宫内暴露于硫嘌呤后儿童青少年期慢性病与先天畸形风险
中位随访8.9年后,调整分析显示类风湿关节炎、炎症性肠病、哮喘及先天畸形的风险均无显著增加。
要点
- 宫内硫嘌呤暴露未增加儿童青少年期七种常见慢性病或先天畸形的风险。
- 类风湿关节炎调整HR为0.78(95%CI 0.35-1.73),先天畸形调整HR为0.95(95%CI 0.78-1.15)。
- 1型糖尿病、乳糜泻、甲状腺病及溃疡性结肠炎因数据不足未行调整分析。
核心结论
- 宫内暴露于硫嘌呤与儿童青少年期七种常见慢性病及先天畸形的风险增加无关。
研究设计与样本
- 暴露组中位随访8.9年(25%-75%分位数5.5-12.4年),非暴露组中位随访13.9年(25%-75%分位数8.7-19.0年)。
- 分析调整了包括母亲基础疾病类型在内的多种混杂因素。
主要发现
- 1047名儿童在宫内暴露于硫嘌呤,随访期间96例诊断为慢性病,126例诊断为先天畸形。
- 类风湿关节炎调整HR为0.78(95%CI 0.35-1.73)。
- 炎症性肠病调整HR为1.45(95%CI 0.64-3.27)。
- 哮喘调整HR为0.94(95%CI 0.73-1.21)。
- 先天畸形调整HR为0.95(95%CI 0.78-1.15)。
关键数值与推荐
- 1型糖尿病、乳糜泻、甲状腺疾病及溃疡性结肠炎因数据不足未进行校正分析。
临床怎么用
- 对于患自身免疫病尤其炎症性肠病的孕妇,可依据本研究结果权衡孕期继续硫嘌呤治疗的长期安全性。
- 需注意1型糖尿病、乳糜泻、甲状腺病及溃疡性结肠炎的长期风险证据尚不充分。
局限性
- 1型糖尿病、乳糜泻、甲状腺疾病及溃疡性结肠炎因数据不足未能进行校正分析。
- 暴露组与非暴露组的中位随访时间存在差异(8.9年 vs 13.9年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Women with autoimmune diseases, particularly inflammatory bowel disease (IBD), often need to continue immunomodulatory therapies during pregnancy. While the evidence of birth and short-term outcomes in children exposed in utero to these medicines is reassuring, long-term safety data are lacking. AIM: To assess any association between in utero exposure to thiopurines and diagnoses of chronic diseases (type 1 diabetes, coeliac disease, thyroid disease, rheumatoid arthritis, IBD and asthma) and congenital malformations during childhood and adolescence. METHODS: This nationwide cohort study was based on information using Danish registers and comprised all live-born children from 1995 to 2015 (N = 1 308 778). Children exposed in utero to thiopurines were followed for a median of 8.9 years (25%-75% percentiles 5.5-12.4 years); children not exposed were followed for 13.9 years (25%-75% percentiles 8.7-19.0 years). Analyses were adjusted for a number of confounders including the type of maternal underlying disease. RESULTS: A total of 1047 children had been exposed to thiopurines in utero; 96 developed a chronic disease and 126 were diagnosed with congenital malformations during follow-up. The adjusted hazard ratio for rheumatoid arthritis was 0.78 (95% CI 0.35-1.73); for IBD, it was 1.45 (95% CI 0.64-3.27); for asthma 0.94 (95% CI 0.73-1.21), and for congenital malformations, it was 0.95 (95% CI 0.78-1.15). For type 1 diabetes, coeliac disease, thyroid disease and ulcerative colitis, we had insufficient data to perform adjusted analysis. CONCLUSION: We found no increased risk of seven common chronic diseases or congenital malformations during childhood and adolescence after gestational exposure to thiopurines.
引用
- Jølving LR, Anru PL, Nielsen J, et al. The risk of chronic diseases and congenital malformations during childhood and adolescence after in utero exposure to thiopurines. Aliment Pharmacol Ther. 2021. PMID: 34464467. doi:10.1111/apt.16578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。